Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magdi Elsallab

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Nature Biotechnology|October 26, 2023
Expanding access to CAR T cell therapies through local manufacturingMagdi Elsallab, Marcela V Maus
Transplantation and Cellular Therapy|March 17, 2024
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector CellsMagdi Elsallab, Florence Bourgeois, Marcela V Maus
Stem Cells Translational Medicine|August 1, 2018
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based InterventionsGerhard Bauer, Magdi Elsallab, Mohamed Abou-El-Enein
Blood|May 22, 2026
In vivo gene therapy with CAR-T cellsDimitrios L Wagner, Magdi Elsallab, Marcela V Maus
Clinical Pharmacology and Therapeutics|December 10, 2024
Mapping the Clinical Development Trajectory of Cell and Gene Therapy ProductsMagdi Elsallab, Michelle Ouvina, Andrea Arfe, et al.
Trends in Molecular Medicine|December 1, 2018
Linking Scattered Stem Cell-Based Data to Advance Therapeutic DevelopmentAndreas Kurtz, Magdi Elsallab, Ralf Sanzenbacher, et al.
Molecular Therapy. Methods & Clinical Development|July 9, 2020
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other BiologicalsMagdi Elsallab, Christopher A Bravery, Andreas Kurtz, et al.
The Lancet. Oncology|February 3, 2020
CAR T-cell product performance in haematological malignancies before and after marketing authorisationMagdi Elsallab, Bruce L Levine, Alan S Wayne, et al.
Cancer Gene Therapy|February 7, 2023
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysisMagdi Elsallab, Moataz Ellithi, Susanne Hempel, et al.
Blood|March 14, 2024
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting SystemMagdi Elsallab, Moataz Ellithi, Matthew A Lunning, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nature Biotechnology|October 26, 2023
Expanding access to CAR T cell therapies through local manufacturingMagdi Elsallab, Marcela V Maus
Transplantation and Cellular Therapy|March 17, 2024
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector CellsMagdi Elsallab, Florence Bourgeois, Marcela V Maus
Stem Cells Translational Medicine|August 1, 2018
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based InterventionsGerhard Bauer, Magdi Elsallab, Mohamed Abou-El-Enein
Blood|May 22, 2026
In vivo gene therapy with CAR-T cellsDimitrios L Wagner, Magdi Elsallab, Marcela V Maus
Clinical Pharmacology and Therapeutics|December 10, 2024
Mapping the Clinical Development Trajectory of Cell and Gene Therapy ProductsMagdi Elsallab, Michelle Ouvina, Andrea Arfe, et al.
Trends in Molecular Medicine|December 1, 2018
Linking Scattered Stem Cell-Based Data to Advance Therapeutic DevelopmentAndreas Kurtz, Magdi Elsallab, Ralf Sanzenbacher, et al.
Molecular Therapy. Methods & Clinical Development|July 9, 2020
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other BiologicalsMagdi Elsallab, Christopher A Bravery, Andreas Kurtz, et al.
The Lancet. Oncology|February 3, 2020
CAR T-cell product performance in haematological malignancies before and after marketing authorisationMagdi Elsallab, Bruce L Levine, Alan S Wayne, et al.
Cancer Gene Therapy|February 7, 2023
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysisMagdi Elsallab, Moataz Ellithi, Susanne Hempel, et al.
Blood|March 14, 2024
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting SystemMagdi Elsallab, Moataz Ellithi, Matthew A Lunning, et al.
Pageof 2